Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-360 in Idiopathic Hypersomnia
NCT06812078Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Feb 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in idiopathic hypersomnia (IH) comparing TAK-360 with Placebo (2 arms). Primary endpoint: Treatment-emergent Adverse Events at 8 weeks. Started Feb 2025; status: recruiting.
02
Drugs
TAK-360
03
Conditions
idiopathic hypersomnia (IH)
Beyond the preview
Go deeper on NCT06812078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812078.